You are here: Industry Insights > Lilly

News List

Lilly Announces Positive Results for Emgality from CONQUER Study americanpharmaceuticalreview
August 07, 2019
Eli Lilly and Company has announced Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 study evaluating the efficacy and safety of Emgality in the preventive treatment of ...
Lilly’s nasal hypoglycaemia therapy receives FDA approval pharmaceutical-technology
July 29, 2019
Eli Lilly has secured the US Food and Drug Administration (FDA) approval for its Baqsimi nasal powder to be used as an emergency treatment for severe hypoglycaemia.
Lilly's Trial Studying Higher Doses of Trulicity® (dulaglutide) Meets Primary Endpoint americanpharmaceuticalreview
June 28, 2019
Eli Lilly and Company's trial studying higher investigational doses of Trulicity® (dulaglutide) met its primary efficacy endpoint of superiority
Lilly enlists patients to raise cluster headache awareness after Emgality scores second nod fiercepharma
June 28, 2019
Cluster headache pain is so intense, one patient describes banging his head against the refrigerator door to make it stop.
Lilly's Trial Studying Higher Doses of Trulicity® (dulaglutide) Meets Primary Endpoint americanpharmaceuticalreview
June 27, 2019
Eli Lilly and Company's trial studying higher investigational doses of Trulicity® (dulaglutide) met its primary efficacy endpoint of superiority, significantly reducing A1C from baseline in people with type 2 diabetes, compared to once-weekly Trulicity 1.
Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of Trajenta® worldpharmanews
June 20, 2019
Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of Trajenta®.
BI, Lilly announces results of new post-hoc analysis of data from the EMPA-REG OUTCOME trial biospectrumasia
June 18, 2019
In this new post-hoc analysis, the effect of empagliflozin on reducing the risk of cardiovascular and kidney outcomes was consistent between people in the EMPA-REG OUTCOME trial who had chronic kidney disease without overt proteinuria and all others in th
Lilly's Tirzepatide Demonstrates Benefits in Data Presented at the American Diabetes Association's® 79ᵗʰ Scientific Sessions drugs
June 13, 2019
Lilly's Tirzepatide Demonstrates Benefits in Data Presented at the American Diabetes Association's® 79ᵗʰ Scientific Sessions.
Lilly and Atomwise partner to use AI for drug discovery pharmaceutical-technology
June 05, 2019
Eli Lilly has formed a multi-target alliance with start-up Atomwise to support preclinical drug discovery efforts.
Lilly licenses non-opioid pain therapeutic from Centrexion pharmaceutical-technology
May 30, 2019
Eli Lilly has signed an agreement to license exclusive global rights for non-opioid pain asset CNTX-0290 from biopharmaceutical company Centrexion Therapeutics.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page